IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors

Science Signaling

Volumn 5, Issue 255, 2012, Pages

  Evdokimova, Valentina ^a,b   Tognon, Cristina E ^c   Benatar, Tania ^a   Yang, Wenyi ^a   Krutikov, Konstantin ^a   Pollak, Michael ^d   Sorensen, Poul H B ^c,e   Seth, Arun ^a  

^a Sunnybrook Health Sciences Centre   (Canada)

^b INSTITUTE OF PROTEIN RESEARCH   (Russian Federation)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CELL SURFACE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXTRACELLULAR SPACE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASM PROTEINS; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84871482509     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003184     Document Type: Article

References (56)

1. A. A. Samani, S. Yakar, D. LeRoith, P. Brodt, The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr. Rev. 28, 20-47 (2007).
2. F. Frasca, G. Pandini, L. Sciacca, V. Pezzino, S. Squatrito, A. Belfiore, R. Vigneri, The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch. Physiol. Biochem. 114, 23-37 (2008).
3. S. A. Rosenzweig, H. S. Atreya, Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol. 80, 1115-1124 (2010).
4. M. Pollak, Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8, 915-928 (2008).
5. M. Pollak, The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat. Rev. Cancer 12, 159-169 (2012).
6. J. C. Potratz, D. N. Saunders, D. H. Wai, T. L. Ng, S. E. McKinney, J. M. Carboni, M. M. Gottardis, T. J. Triche, H. Jürgens, M. N. Pollak, S. A. Aparicio, P. H. Sorensen, Synthetic lethality screens reveal RPS6 andMST1R asmodifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res. 70, 8770-8781 (2010).
7. C. I. Campbell, R. A. Moorehead, Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors. BMC Cancer 11, 480 (2011).
8. E. Buck, M. Mulvihill, Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin. Investig. Drugs 20, 605-621 (2011).
9. A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, R. Vigneri, Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 30, 586-623 (2009).
10. S. M. Firth, R. C. Baxter, Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23, 824-854 (2002).
11. V. Hwa, Y. Oh, R. G. Rosenfeld, The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 20, 761-787 (1999).
12. A. M. Burger, B. Leyland-Jones, K. Banerjee, D. D. Spyropoulos, A. K. Seth, Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur. J. Cancer 41, 1515-1527 (2005).
13. Y. Oh, S. R. Nagalla, Y. Yamanaka, H. S. Kim, E. Wilson, R. G. Rosenfeld, Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J. Biol. Chem. 271, 30322-30325 (1996).
14. K. Akaogi, J. Sato, Y. Okabe, Y. Sakamoto, H. Yasumitsu, K. Miyazaki, Synergistic growth stimulation of mouse fibroblasts by tumor-derived adhesion factor with insulin-like growth factors and insulin. Cell Growth Differ. 7, 1671-1677 (1996).
15. Y. Yamanaka, E. M. Wilson, R. G. Rosenfeld, Y. Oh, Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J. Biol. Chem. 272, 30729-30734 (1997).
16. Y. Sato, Z. Chen, K. Miyazaki, Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/ mac25. Cancer Sci. 98, 1055-1063 (2007).
17. S. J. Santner, P. J. Dawson, L. Tait, H. D. Soule, J. Eliason, A. N. Mohamed, S. R. Wolman, G. H. Heppner, F. R. Miller, Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 65, 101-110 (2001).
18. D. Yee, G. S. Lebovic, R. R. Marcus, N. Rosen, Identification of an alternate type I insulin-like growth factor receptor b subunit mRNA transcript. J. Biol. Chem. 264, 21439-21441 (1989).
19. A. Hollestelle, F. Elstrodt, J. H. Nagel,W.W. Kallemeijn, M. Schutte, Phosphatidylinositol-3- OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 5, 195-201 (2007).
20. G. M. Yanochko, W. Eckhart, Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res. 8, R18 (2006).
21. C. E. Tognon, A. M. Somasiri, V. E. Evdokimova, G. Trigo, E. E. Uy, N. Melnyk, J. M. Carboni, M. M. Gottardis, C. D. Roskelley, M. Pollak, P. H. Sorensen, ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res. 71, 1060-1070 (2011).
22. D. K. Armstrong, S. H. Kaufmann, Y. L. Ottaviano, Y. Furuya, J. A. Buckley, J. T. Isaacs, N. E. Davidson, Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res. 54, 5280-5283 (1994).
23. H. Zhang, A. M. Pelzer, D. T. Kiang, D. Yee, Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 67, 391-397 (2007).
24. E. Buck, P. C. Gokhale, S. Koujak, E. Brown, A. Eyzaguirre, N. Tao, M. Rosenfeld-Franklin, L. Lerner, M. I. Chiu, R. Wild, D. Epstein, J. A. Pachter, M. R. Miglarese, Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 9, 2652-2664 (2010).
25. J. Sato, S. Hasegawa, K. Akaogi, H. Yasumitsu, S. Yamada, K. Sugahara, K. Miyazaki, Identification of cell-binding site of angiomodulin (AGM/TAF/Mac25) that interacts with heparan sulfates on cell surface. J. Cell. Biochem. 75, 187-195 (1999).
26. J. Kishibe, S. Yamada, Y. Okada, J. Sato, A. Ito, K. Miyazaki, K. Sugahara, Structural requirements of heparan sulfate for the binding to the tumor-derived adhesion factor/ angiomodulin that induces cord-like structures to ECV-304 human carcinoma cells. J. Biol. Chem. 275, 15321-15329 (2000).
27. P. Zhou, Determining protein half-lives. Methods Mol. Biol. 284, 67-77 (2004).
28. A. C. Gingras, B. Raught, N. Sonenberg, eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68, 913-963 (1999).
29. A. C. Gingras, S. G. Kennedy, M. A. O 'Leary, N. Sonenberg, N. Hay, 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12, 502-513 (1998).
30. S. Li, N. Sonenberg, A. C. Gingras, M. Peterson, S. Avdulov, V. A. Polunovsky, P. B. Bitterman, Translational control of cell fate: Availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol. Cell. Biol. 22, 2853-2861 (2002).
31. B. A. Jacobson, M. D. Alter, M. G. Kratzke, S. P. Frizelle, Y. Zhang, M. S. Peterson, S. Avdulov, R. P. Mohorn, B. A. Whitson, P. B. Bitterman, V. A. Polunovsky, R. A. Kratzke, Repression of cap-dependent translation attenuates the transformed phenotype in non- small cell lung cancer both in vitro and in vivo. Cancer Res. 66, 4256 -4262 (2006).
32. Q. B. She, E. Halilovic, Q. Ye,W. Zhen, S. Shirasawa, T. Sasazuki, D. B. Solit, N. Rosen, 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18, 39-51 (2010).
33. J. H. Law, G. Habibi, K. Hu, H. Masoudi, M. Y. Wang, A. L. Stratford, E. Park, J. M. Gee, P. Finlay, H. E. Jones, R. I. Nicholson, J. Carboni, M. Gottardis, M. Pollak, S. E. Dunn, Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68, 10238-10246 (2008).
34. R. Yerushalmi, K. A. Gelmon, S. Leung, D. Gao, M. Cheang, M. Pollak, G. Turashvili, B. C. Gilks, H. Kennecke, Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res. Treat. 132, 131-142 (2012).
35. P. Fu, M. Ibusuki, Y. Yamamoto, M. Hayashi, K. Murakami, S. Zheng, H. Iwase, Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression. Breast Cancer Res. Treat. 130, 307- 317 (2011).
36. Y. Amemiya, W. Yang, T. Benatar, S. Nofech-Mozes, A. Yee, H. Kahn, C. Holloway, A. Seth, Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res. Treat. 126, 373-384 (2011).
37. T. Benatar, W. Yang, Y. Amemiya, V. Evdokimova, H. Kahn, C. Holloway, A. Seth, IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res. Treat. 133, 563-573 (2012).
38. N. Wajapeyee, V. Kapoor, M. Mahalingam, M. R. Green, Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Mol. Cancer Ther. 8, 3009-3014 (2009).
39. C. Sell, G. Dumenil, C. Deveaud, M. Miura, D. Coppola, T. DeAngelis, R. Rubin, A. Efstratiadis, R. Baserga, Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 14, 3604 - 3612 (1994).
40. C. E. Tognon, M. J. Martin, A. Moradian, G. Trigo, B. Rotblat, S. W. G. Cheng, M. Pollard, E. Uy, C. Chow, J. M. Carboni, M. M. Gottardis, M. Pollak, G. B. Morin, P. H. B. Sorensen, A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene 31, 1334-1340 (2012).
41. S.Ahmed, X. Jin, M.Yagi,C.Yasuda,Y.Sato, S.Higashi, C. Y. Lin, R.B. Dickson, K. Miyazaki, Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). FEBS J. 273, 615-627 (2006).
42. A. R. Tee, C. G. Proud, Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif. Mol. Cell. Biol. 22, 1674-1683 (2002).
43. N. Wajapeyee, R. W. Serra, X. Zhu, M. Mahalingam, M. R. Green, Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132, 363-374 (2008).
44. M. Wittman, J. Carboni, R. Attar, B. Balasubramanian, P. Balimane, P. Brassil, F. Beaulieu, C. Chang, W. Clarke, J. Dell, J. Eummer, D. Frennesson, M. Gottardis, A. Greer, S. Hansel, W. Hurlburt, B. Jacobson, S. Krishnananthan, F. Y. Lee, A. Li, T. A. Lin, P. Liu, C. Ouellet, X. Sang, M. G. Saulnier, K. Stoffan,Y. Sun, U.Velaparthi, H.Wong, Z. Yang, K.Zimmermann, M. Zoeckler, D. Vyas, Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS- 536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J. Med. Chem. 48, 5639-5643 (2005).
45. D. Vasilcanu, A. Girnita, L. Girnita, R. Vasilcanu, M. Axelson, O. Larsson, The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/ Akt apoptotic pathway. Oncogene 23, 7854-7862 (2004).
46. S. Mohseni-Zadeh, M. Binoux, Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: An alternative mechanism in the regulation of IGF action. Endocrinology 138, 5645-5648 (1997).
47. J. M. Ricort, M. Binoux, Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinology 142, 108-113 (2001).
48. C. Lalou, C. Lassarre, M. Binoux, A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137, 3206-3212 (1996).
49. J. Boucher, Y. Macotela, O. Bezy, M. A. Mori, K. Kriauciunas, C. R. Kahn, A kinaseindependent role for unoccupied insulin and IGF-1 receptors in the control of apoptosis. Sci. Signal. 3, ra87 (2010).
50. V. Evdokimova, P. Ruzanov, M. S. Anglesio, A. V. Sorokin, L. P. Ovchinnikov, J. Buckley, T. J. Triche, N. Sonenberg, P. H. B. Sorensen, Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol. Cell. Biol. 26, 277-292 (2006).
51. S. Qi, Y. Song, Y. Peng, H. Wang, H. Long, X. Yu, Z. Li, L. Fang, A. Wu, W. Luo, Y. Zhen, Y. Zhou, Y. Chen, C. Mai, Z. Liu, W. Fang, ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLos One 7, e38842 (2012).
52. Y. Wang, P. Nangia-Makker, V. Balan, V. Hogan, A. Raz, Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment. Cell Death Dis. 1, e101 (2010).
53. E. Agbottah, W.I. Yeh, R. Berro, Z. Klase, C. Pedati, K. Kehn-Hall,W.Wu, F.Kashanchi, Two specific drugs, BMS-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways. AIDS Res. Ther. 5, 12 (2008).
54. Y. Zhuang, W. K. Miskimins, Metformin induces both caspase-dependent and poly (ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol. Cancer Res. 9, 603-615 (2011).
55. J. Deng, T. Shimamura, S. Perera, N. E. Carlson, D. Cai, G. I. Shapiro, K. K. Wong, A. Letai, Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 67, 11867- 11875 (2007).
56. M. Toulany, T. A. Schickfluss, W. Eicheler, R. Kehlbach, B. Schittek, H. P. Rodemann, Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation. Breast Cancer Res. 13, R28 (2011).